Weekly Analysts’ Ratings Updates for Compass Pathways (CMPS)

Several brokerages have updated their recommendations and price targets on shares of Compass Pathways (NASDAQ: CMPS) in the last few weeks:

• 7/8/2026 – Compass Pathways had its “buy” rating reaffirmed by HC Wainwright. They now have a $70.00 price target on the stock.
• 7/8/2026 – Compass Pathways was upgraded by Evercore Inc from “in-line” to “outperform”. They now have a $21.00 price target on the stock.
• 7/7/2026 – Compass Pathways had its price target raised by Stifel Nicolaus from $14.00 to $21.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Compass Pathways had its “outperform” rating reaffirmed by Wolfe Research.
• 7/7/2026 – Compass Pathways was given a new $25.00 price target by Compass Point.
• 7/7/2026 – Compass Pathways had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $20.00 price target on the stock.
• 7/7/2026 – Compass Pathways had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 7/7/2026 – Compass Pathways had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $17.00 price target on the stock.
• 7/7/2026 – Compass Pathways had its price target raised by BTIG Research from $14.00 to $25.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Compass Pathways had its price target raised by Canaccord Genuity Group Inc. from $18.00 to $20.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Compass Pathways had its “buy” rating reaffirmed by TD Cowen.
• 5/22/2026 – Compass Pathways had its “buy” rating reaffirmed by Raymond James Financial, Inc..
• 5/22/2026 – Compass Pathways had its “buy” rating reaffirmed by HC Wainwright.
• 5/22/2026 – Compass Pathways is now covered by Wolfe Research. They set an “outperform” rating on the stock.

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.